Glenmark gets final approval for gWelchol suspension, completes Zorg acquisition
Glenmark Pharma has received final USFDA approval for Colesevelam HCL for Oral Suspension in two strengths (1.875 grams/Packet and 3.75 grams/Packet). This is a generic version of Welchol of Daiichi Sankyo Inc. Company has also informed that it has completed acquisition of the 100% equity stake in Zorg for Rs5 lakh. Zorg is a pune based compnay which had annual sales of Rs36 lakh in FY17.
According to IQVIATM sales data for the 12-month period ending May 2018, Welchol Oral Suspension (1.875 grams/Packet and 3.75 grams/Packet) achieved annual sales of ~$73.0mn.
Welchol is a statin alternative, which helps in lowering cholesterol. Glenmark and Sun Pharma in May 2018 received final USFDA approval for gWelchol tablets 625mg. Welchol 625mg tablet had US sales of $520mn for 12-month period ending March 2018.
Glenmark’s has 138 products authorized for distribution in the US market and its 62 ANDAs are pending for approval.
Best services for customers with full technical support make your Financial Trading more easy click here to subscribe us for free >>Bonaz Capital